The targets for immunotherapy in NSCLC patients are PD-L1 (Programmed Cell Death-Ligand 1), PD-1 (Programmed Cell Death 1), and CTLA-4 (Cytotoxic T Lymphocyte Antigen 4) [1,2]. The gene discussed is PDCD1; the disease is non-small cell lung carcinoma.